Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amikacin Sulfate

FDA-approved product (injectable, injection), marketed as Amikacin Sulfate, Amikacin Sulfate In Sodium Chloride 0.9% In Plastic Container, Amikin and 2 more.

Registered studies
50+
Lab records
133
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Amikacin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection
  • Infectious meningitis
  • Lung disease
  • Peritonitis
  • Respiratory tract infectious disorder
  • Sepsis
  • Staphylococcus aureus infection
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use; Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB06; WHO ATC D06AX12; WHO ATC S01AA21; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Amikacin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae84.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 6 of 8 lab records
  • K. pneumoniae: measured active in 73 of 115 lab records
  • M. tuberculosis: measured active in 9 of 9 lab records
Open Amikacin Sulfate in ChEMBL Registered studies below
Show the 133 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amikacin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

    NCT06238856 · start 2004-05-12

    Registered record
    Registry ID
    NCT06238856
    Conditions
    Cystic Fibrosis
    Interventions
    SLIT™ Amikacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-05-12
    Completion
    2005-02-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionSLIT™ Amikacin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

    NCT00153634 · start 2004-03

    Registered record
    Registry ID
    NCT00153634
    Conditions
    Cystic Fibrosis; Chronic Bronchitis
    Interventions
    IV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin; IV meropenem; IV piperacillin-tazobactam; IV ticarcillin-clavulanate; IV tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-03
    Completion
    2007-11
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Chronic Bronchitis
    InterventionIV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children

    NCT00129688 · start 2002-04

    Registered record
    Registry ID
    NCT00129688
    Conditions
    Neutropenia; Cancer; Fever
    Interventions
    cloxacillin and amikacin (once or twice daily dosage)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-04
    Completion
    2004-06
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia; Cancer; Fever
    Interventioncloxacillin and amikacin (once or twice daily dosage)
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

    NCT00035425 · start 2001-11

    Registered record
    Registry ID
    NCT00035425
    Conditions
    Febrile Neutropenia
    Interventions
    linezolid; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2002-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    Interventionlinezolid; vancomycin
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

    NCT01315691

    Registered record
    Registry ID
    NCT01315691
    Conditions
    Cystic Fibrosis
    Interventions
    Liposomal amikacin for inhalation; Placebo for liposomal amikacin for inhalation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionLiposomal amikacin for inhalation; Placebo for liposomal amikacin for inhalation
    PhasePhase 3
    Registry statusWithdrawn